Biography
Dr. Mohammad-Ali Shahbazi
Current research
Dr. Shahbazi is the leader of the Biopharmaceuticals, Discovery, Design, and Delivery (BDDD) Research Program at the Personalized Medicine Research Institute Groningen (PRECISION) and holds an honorary adjunct fellowship at the Faculty of Health, University of Technology Sydney, Australia. He is also the co-founder of Capsamedix Company, which is engaged in advancing 3D-printed devices for localized drug delivery in the oral cavity.
He obtained his PhD from the University of Helsinki, Finland, in 2015. Following a year of postdoctoral research at the same institution, he became a part of the BioLabChip group at the Department of Micro- and Nanotechnology, Technical University of Denmark. In 2018, he secured a prestigious grant from the Academy of Finland, spanning three years, to develop thermo-responsive microimplants for the treatment of autoimmune disorders.
Dr. Shahbaziʼs influential standing within his research domain is substantiated by an extensive publication record, including over 210 articles in distinguished journals, a book, 16 book chapters, and more than 200 conference presentations. Moreover, he actively contributes to the scientific community via his role as the editor of the Chemical Engineering Journal and as an editorial board member of three journals in the areas of drug delivery and biomaterials. Additionally, he has consistently contributed as a reviewer to more than 60 reputable peer-reviewed journals.
Dr. Shahbazi has been associated with the Controlled Release Society since 2013 as an active member and is currently a board member of the Controlled Release Society’s Transdermal and Mucosal Delivery Focus Group. He boasts a collection of competitive international grants and awards, encompassing the University of Helsinki's Best PhD Dissertation Award, recognition for the best PhD thesis in pharmaceutical Sciences in Finland, the prestigious Young Researcher Award from the 20th Razi Festival, and the USERN Laureate Prize in 2020. He was also recognized as an emerging investigator by the Nanoscale Journal of the Royal Society of Chemistry and as an emerging voice in drug delivery by the editorial members of the Advanced Drug Delivery Reviews journal.
Dr. Shahbazi has extensive expertise in nano-based drug delivery systems, and his research focus centers on reshaping the trajectory of multifunctional medications by merging material science, biology, and nanotechnology. He has developed inventive nanoparticulate delivery platforms and employed them across a diverse spectrum of clinical targets. Moreover, his endeavors encompass years of work on augmenting and modifying the properties of nanomaterials, including improved cellular internalization and targeted localization. His present emphasis is on fabricating novel 3D hydrogels with applications in local drug delivery and tissue regeneration. Furthermore, he is engaged in developing photoactive nanomaterials and biomimetic carriers for therapeutic and regenerative purposes.